YongTai Berhad (7066) vs Foresight of the vaccine market - Part 1 YongTai Berhad (7066) vs Foresight of the vaccine market - Part 2 YongTai Berhad (7066) vs Foresight of the vaccine market - Part 3
gap up! done sold all. I wait for the gap to be filled first and collect more later at the bottom cause gap always been filled before moving further up, that's why the director is selling after the gap up lol. huat ar!
Today 4/6/21 just now minister of health announced government Malaysia had put in ordered for 109% population Malaysia doses. So, yongtai afternoon Will water fall. Faster sell
What about Kanger? Does it has a solid distribution agreement for sinopharm vaccine. What is the status of sinopharm vaccine with NRPA. WHO approved it a while back, Ready to go once approved? A better option than YT?
agree with you. notice the price queue change again? now forcing lower at 0.28.. conman laughing at you all who went in and trapped and cut loss. ha ha ha
Trust What about Kanger? Does it has a solid distribution agreement for sinopharm vaccine. What is the status of sinopharm vaccine with NRPA. WHO approved it a while back, Ready to go once approved? A better option than YT?
-------------------------------------
Some information on the approval of Sinopharm Covid-19 vaccines and other vaccines by WHO. A theory relating the status of Sinopharm Covid_19 vaccine application with NPRA also can be referred in this article.
Article: Is It True That The Process of Registering The Sinopharm Vaccine (With NPRA) Has Started?
The 15-19 months are full cycle for phase 3. It's normal for such a trial test.
But bear in mind this is an extraordinary situation with this pandemic. After 2 months into the trial, with the accelerated data already can bring in bulk vaccines
enyataan Akhbar KPK 5 Jun 2021 – Kajian Klinikal Produk SARS-CoV-2 Vaccine (Vero Cells), Inactivated Keluaran Shenzhen Kangtai Biological Products Co., Ltd., China BY DG OF HEALTH ON JUNE 5, 2021
Kementerian Kesihatan Malaysia (KKM) ingin memaklumkan bahawa terdapat tambahan satu (1) kajian klinikal yang melibatkan vaksin COVID-19 telah diluluskan oleh Bahagian Regulatori Farmasi Negara (NPRA) pada 28 Mei 2021. Kajian klinikal ini melibatkan produk SARS-CoV-2 Vaccine (Vero Cells), Inactivated, 5μg/0.5mL yang dikilangkan oleh pengilang Shenzhen Kangtai Biological Products Co., Ltd. di negara China.
Kajian Klinikal Fasa 3 ini akan dijalankan di lapan (8) pusat penyelidikan di Malaysia dengan sasaran peserta sebanyak 3,000 orang dewasa yang berumur 18 tahun dan ke atas serta dijangka akan mengambil masa selama 15 hingga 19 bulan. Malaysia merupakan salah sebuah negara yang terlibat dalam kajian klinikal ini selain daripada Colombia, Argentina, Pakistan, Filipina dan Ukraine. Vaksin ini juga telah diluluskan oleh negara China melalui Emergency Use Approval pada 14 Mei 2021.
Kajian klinikal vaksin COVID-19 yang dijalankan di Malaysia dapat memberikan maklumat klinikal yang berkaitan dengan keberkesanan dan keselamatan vaksin, serta maklumat berkenaan kesesuaian vaksin kepada rakyat Malaysia. Ini merupakan kelebihan yang diperlukan oleh kerajaan untuk memacu ke arah capaian sasaran imuniti kelompok (herd immunity) melalui Program Imunisasi COVID-19 Kebangsaan yang sedang giat dijalankan di seluruh negara.
TAN SRI DATO’ SERI DR. NOOR HISHAM BIN ABDULLAH
KETUA PENGARAH KESIHATAN MALAYSIA
5 Jun 2021
Post a Comment
People who like this
New Topic
You should check in on some of those fields below.
Title
Category
Comment
Confirmation
Click Confirm to delete this Forum Thread and all the associated comments.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
williamtkb
3,216 posts
Posted by williamtkb > 2021-06-04 09:32 | Report Abuse
By the time yongtai vaccine approved by WHO. All Malaysian vaccinated sinovac, pfizer and AZ which monopoly by pharma and dpharma.